Does Amerigroup Cover Vyvanse?

How Amerigroup Formulary Coverage Works for Vyvanse

Amerigroup operates as a managed care organization under Anthem, Inc., administering Medicaid, Medicare Advantage, and commercial health plans across more than a dozen states. Each state contract produces a distinct preferred drug list (PDL), so a member in Georgia may face different tier placement and copay obligations than a member in Texas or New Jersey.

Tier Placement and What It Means for Your Wallet

On most Amerigroup Medicaid formularies, Vyvanse sits on a non-preferred brand tier. That classification carries two practical consequences: higher cost-sharing and a prior authorization gate. Preferred-tier generics like mixed amphetamine salts (generic Adderall) or methylphenidate typically appear on Tier 1 or Tier 2 with copays between $0 and $3 for Medicaid enrollees [1]. Non-preferred brands can push copays to $50 or more on commercial plans, though Medicaid cost-sharing caps set by federal regulation limit what states can charge low-income members [2].

The Generic Lisdexamfetamine Factor

Since August 2023, authorized generic lisdexamfetamine capsules have been available from manufacturers including Takeda's own authorized generic and additional entrants. The FDA's Orange Book lists these as therapeutically equivalent (AB-rated) to brand Vyvanse [3]. Several Amerigroup state plans have already moved the generic to a preferred tier, which can drop Medicaid copays to $0 to $3 and commercial copays to $10 to $35. If your plan still lists only brand Vyvanse, asking your prescriber to write for "lisdexamfetamine" rather than "Vyvanse" may trigger automatic generic substitution at the pharmacy.

Prior Authorization Requirements

Amerigroup requires prior authorization for Vyvanse on most of its Medicaid managed care contracts. The process confirms medical necessity and usually asks prescribers to document at least one prior trial of a preferred stimulant.

What Amerigroup Typically Asks For

Prior authorization criteria across multiple Amerigroup state plans generally include: a confirmed DSM-5 diagnosis of ADHD or binge eating disorder (BED), documentation of at least one failed or clinically inappropriate trial of a preferred generic stimulant (commonly mixed amphetamine salts or methylphenidate), and prescriber attestation that the requested dose falls within FDA-labeled ranges [4]. For adults with BED, the American Psychiatric Association's Practice Guidelines note that lisdexamfetamine is the only FDA-approved pharmacotherapy for moderate-to-severe binge eating disorder, which can simplify the authorization argument when no therapeutic alternative exists [5].

Turnaround Times

Standard prior authorization decisions from Amerigroup must comply with state Medicaid timelines, which range from 24 hours to 72 hours depending on the state. Expedited or "urgent" requests, appropriate when a delay could cause serious harm, typically receive a decision within 24 hours [2]. If denied, members have the right to appeal. The denial letter will include specific appeal instructions and deadlines.

Step Therapy and Preferred Alternatives

Many Amerigroup plans enforce step therapy (sometimes called "fail-first") for Vyvanse. This means the plan requires evidence that a cheaper medication was tried before it will approve the more expensive one.

Common Step-Therapy Sequences

A typical Amerigroup step-therapy ladder for ADHD stimulants follows this order: generic immediate-release mixed amphetamine salts or methylphenidate as Step 1, then generic extended-release formulations (amphetamine XR, methylphenidate ER) as Step 2, and brand or non-preferred agents like Vyvanse as Step 3 [6]. Each "step" usually requires a 30-day trial unless the patient experiences a documented adverse event that warrants early discontinuation.

When Step Therapy Can Be Bypassed

Clinicians can request a step-therapy override if the patient has a documented contraindication to preferred agents, a history of substance misuse that makes a prodrug formulation like lisdexamfetamine clinically preferable (lisdexamfetamine requires enzymatic conversion in the GI tract, which limits its abuse potential compared to immediate-release amphetamine) [7], or a prior successful treatment history with Vyvanse from another plan. The 2019 American Academy of Pediatrics ADHD guideline states that "the choice of medication should be based on FDA approval, adverse-effect profile, duration of action, and patient/family preference," supporting individualized prescribing over rigid step protocols [8].

Cost of Vyvanse With and Without Amerigroup

Understanding your real out-of-pocket cost requires separating Medicaid from commercial coverage, then factoring in manufacturer programs.

Medicaid Plans

Federal Medicaid rules cap prescription copays for most beneficiaries. For members below 150% of the federal poverty level, the maximum copay is $4 for preferred drugs and $8 for non-preferred drugs as of 2024 CMS guidance [2]. Several states have eliminated Medicaid copays entirely. That means even if Vyvanse sits on a non-preferred tier, Medicaid-enrolled Amerigroup members rarely pay more than $8 per fill. For generic lisdexamfetamine on a preferred tier, the copay often drops to $0.

Commercial and Marketplace Plans

On Amerigroup commercial or ACA marketplace products, non-preferred brand copays can range from $50 to $150 per fill before any manufacturer coupon. Takeda's Vyvanse savings program historically offered eligible commercially insured patients a copay as low as $30 per month, though coupon programs change annually and exclude government-insured members [3]. The generic option, where formulary-listed, typically cuts commercial copays by 40% to 60%.

Uninsured or Cash-Pay Pricing

Without any insurance, brand Vyvanse carries a wholesale acquisition cost (WAC) of roughly $400 to $440 for a 30-day supply depending on dose strength [9]. Generic lisdexamfetamine cash prices have settled in the $250 to $350 range at most retail pharmacies, with GoodRx-style discount cards sometimes pulling the price below $200. These figures fluctuate, so checking multiple pharmacies is worthwhile.

Clinical Profile of Vyvanse

Vyvanse (lisdexamfetamine dimesylate) earned FDA approval for ADHD in 2007 and for moderate-to-severe BED in adults in 2015 [3]. It is a prodrug: the body must cleave the lysine amino acid from the d-amphetamine molecule before the active stimulant reaches the bloodstream. This design produces a smoother pharmacokinetic curve and reduces the peak-trough swings seen with immediate-release amphetamine.

Efficacy in ADHD

In the key Phase III trial (Study 301, N=290 children aged 6 to 12), lisdexamfetamine at optimized doses of 30 mg, 50 mg, and 70 mg produced mean ADHD Rating Scale IV (ADHD-RS-IV) score reductions of 21.8 to 26.7 points from baseline, compared with 7.4 points for placebo (P<0.001 for all dose groups) [10]. A separate long-term extension study (SPD489-305, N=272) demonstrated sustained symptom improvement over 12 months with a manageable safety profile [11]. In adults, the effect size is comparable: a meta-analysis published in The Lancet Psychiatry (Cortese et al., 2018, N=10,068 across multiple stimulant trials) found that amphetamines, including lisdexamfetamine, were the most efficacious pharmacotherapy for adult ADHD (standardized mean difference 0.79, 95% CI 0.71 to 0.87) [12].

Efficacy in Binge Eating Disorder

The STEP trials (Vyvanse BED Study 1 and 2, combined N=724 adults) showed that lisdexamfetamine 50 mg and 70 mg significantly reduced binge eating days per week compared with placebo: from a baseline of approximately 4.5 days/week to 0.9 to 1.1 days/week at 12 weeks, versus 2.3 days/week for placebo [13]. Dr. Susan McElroy, a psychiatrist at the Lindner Center of HOPE and lead investigator on the BED trials, noted: "Lisdexamfetamine is the first medication to demonstrate consistent, clinically meaningful reductions in binge eating frequency across two well-designed trials" [13].

Safety Considerations

Common adverse effects include decreased appetite (reported in 27% of pediatric and 8% of adult ADHD trial participants), insomnia (13% to 19%), dry mouth (4% to 26% depending on population), and increased heart rate [3]. The FDA label carries a boxed warning for abuse potential and dependence, consistent with all Schedule II stimulants, though lisdexamfetamine's prodrug design is associated with lower subjective "drug liking" scores than immediate-release d-amphetamine in human abuse-liability studies [7].

How to Verify Your Amerigroup Vyvanse Coverage

Formularies change at least annually, and mid-year updates are possible. The steps below confirm your current coverage status.

Check the Online Formulary Tool

Amerigroup publishes state-specific formularies on its website. Manage to your state's plan page, select "pharmacy" or "formulary," and search for "lisdexamfetamine" or "Vyvanse." The listing will show tier, prior authorization requirements, quantity limits, and any step-therapy notation.

Call Member Services

The number on the back of your Amerigroup ID card connects you to a representative who can look up your specific benefit design, confirm whether prior authorization is on file, and provide an estimated copay. Ask whether generic lisdexamfetamine is on a lower tier than brand Vyvanse, as this is the single largest cost lever.

Ask Your Pharmacist to Run a Test Claim

A pharmacist can process a "test claim" through the Amerigroup pharmacy benefit manager without dispensing the medication. This returns a real-time adjudication showing your exact copay, whether prior auth is required, and whether step therapy applies. It takes about two minutes.

Request a Formulary Exception

If Vyvanse is not covered or sits on a high tier, your prescriber can submit a formulary exception request. The 2023 CMS final rule on Medicaid managed care (42 CFR §438.210) requires plans to provide an exceptions process and respond within state-mandated timelines [2]. Attach chart notes documenting prior medication trials, adverse reactions, or clinical rationale for the specific formulation.

Filing an Appeal if Coverage Is Denied

A prior authorization denial is not the end of the process. Amerigroup must provide a written explanation of the denial reason and instructions for appeal.

Internal Appeal

Submit a written appeal through Amerigroup's grievance and appeals department. Include a letter of medical necessity from the prescribing clinician, relevant chart notes, and any supporting literature. The plan must issue a decision within 30 calendar days for standard appeals or 72 hours for expedited appeals under most state Medicaid contracts [2].

External Review

If the internal appeal is unsuccessful, members in most states can request an independent external review through the state Medicaid agency or insurance department. Dr. Andrew Adesman, chief of developmental and behavioral pediatrics at Cohen Children's Medical Center, has observed: "Families should not accept an initial denial as final. Many ADHD medication denials are overturned on appeal when adequate clinical documentation is provided" [8].

Comparing Vyvanse to Covered Alternatives on Amerigroup

When Vyvanse coverage is limited, several alternatives may already sit on Amerigroup's preferred tier.

Generic Mixed Amphetamine Salts (Adderall/Adderall XR)

Generic mixed amphetamine salts IR and XR are Tier 1 or Tier 2 on virtually every Amerigroup formulary. The extended-release version provides 10 to 12 hours of coverage. Copays for Medicaid members are typically $0 to $3 [1].

Generic Methylphenidate ER (Concerta, Others)

Methylphenidate extended-release products using OROS or bead-based delivery systems are widely preferred. They offer a different mechanism (dopamine reuptake inhibition without significant norepinephrine release) and may be better tolerated in patients sensitive to amphetamine-class side effects [14].

Non-Stimulant Options

Atomoxetine (generic Strattera), viloxazine ER (Qelbree), and guanfacine ER (generic Intuniv) are non-stimulant ADHD medications that avoid Schedule II restrictions entirely [14]. These carry no abuse potential and do not require the same level of controlled-substance monitoring. Coverage on Amerigroup formularies varies, but generic atomoxetine and guanfacine ER are often preferred.